These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

76 related items for PubMed ID: 12211437

  • 1. Long-term predictions of the therapeutic equivalence of daily and less than daily alendronate dosing.
    Hernandez CJ, Beaupré GS, Marcus R, Carter DR.
    J Bone Miner Res; 2002 Sep; 17(9):1662-6. PubMed ID: 12211437
    [Abstract] [Full Text] [Related]

  • 2. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ.
    Aging (Milano); 2000 Feb; 12(1):1-12. PubMed ID: 10746426
    [Abstract] [Full Text] [Related]

  • 3. Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis.
    Rizzoli R, Greenspan SL, Bone G, Schnitzer TJ, Watts NB, Adami S, Foldes AJ, Roux C, Levine MA, Uebelhart B, Santora AC, Kaur A, Peverly CA, Orloff JJ, Alendronate Once-Weekly Study Group.
    J Bone Miner Res; 2002 Nov; 17(11):1988-96. PubMed ID: 12412806
    [Abstract] [Full Text] [Related]

  • 4. Patients with osteoporosis prefer once weekly to once daily dosing with alendronate.
    Kendler D, Kung AW, Fuleihan Gel-H, González González JG, Gaines KA, Verbruggen N, Melton ME.
    Maturitas; 2004 Jul 15; 48(3):243-51. PubMed ID: 15207890
    [Abstract] [Full Text] [Related]

  • 5. Antiresorption therapy and reduction in fracture susceptibility in the osteoporotic elderly patient: open study.
    Muscoso E, Puglisi N, Mamazza C, Lo Giudice F, Testai M, Abbate S, Santangelo A, Panebianco P, Maugeri D.
    Eur Rev Med Pharmacol Sci; 2004 Jul 15; 8(2):97-102. PubMed ID: 15267123
    [Abstract] [Full Text] [Related]

  • 6. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F.
    Clin Endocrinol (Oxf); 2004 May 15; 60(5):568-75. PubMed ID: 15104559
    [Abstract] [Full Text] [Related]

  • 7. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis.
    Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ.
    J Clin Invest; 1997 Sep 15; 100(6):1475-80. PubMed ID: 9294113
    [Abstract] [Full Text] [Related]

  • 8. Osteoporosis. Efficacy and safety of a bisphosphonate dosed once weekly.
    Baran D.
    Geriatrics; 2001 Mar 15; 56(3):28-32. PubMed ID: 11252758
    [Abstract] [Full Text] [Related]

  • 9. [Simulation through the method of finite element of alendronate in a model of bone remodeling based on damage mechanics].
    Zeman ME, García JM, Doblaré M.
    Acta Cient Venez; 2003 Mar 15; 54(1):36-42. PubMed ID: 14515765
    [Abstract] [Full Text] [Related]

  • 10. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy.
    Miller PD.
    Clin Ther; 2005 Apr 15; 27(4):361-76. PubMed ID: 15922811
    [Abstract] [Full Text] [Related]

  • 11. Can the increase of bone mineral density following bisphosphonates treatments be explained by biomechanical considerations?
    Pioletti DP, Rakotomanana LR.
    Clin Biomech (Bristol, Avon); 2004 Feb 15; 19(2):170-4. PubMed ID: 14967580
    [Abstract] [Full Text] [Related]

  • 12. Alendronate prevents further bone loss in renal transplant recipients.
    Giannini S, D'Angelo A, Carraro G, Nobile M, Rigotti P, Bonfante L, Marchini F, Zaninotto M, Dalle Carbonare L, Sartori L, Crepaldi G.
    J Bone Miner Res; 2001 Nov 15; 16(11):2111-7. PubMed ID: 11697808
    [Abstract] [Full Text] [Related]

  • 13. Early changes in biochemical markers of bone turnover predict the long-term response to alendronate therapy in representative elderly women: a randomized clinical trial.
    Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB.
    J Bone Miner Res; 1998 Sep 15; 13(9):1431-8. PubMed ID: 9738515
    [Abstract] [Full Text] [Related]

  • 14. Clinical evaluation of novel bisphosphonate dosing regimens in osteoporosis: the role of comparative studies and implications for future studies.
    Cosman F, Borges JL, Curiel MD.
    Clin Ther; 2007 Jun 15; 29(6):1116-27. PubMed ID: 17692726
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of alendronate for the treatment of osteoporosis in diffuse connective tissue diseases in children: a prospective multicenter study.
    Bianchi ML, Cimaz R, Bardare M, Zulian F, Lepore L, Boncompagni A, Galbiati E, Corona F, Luisetto G, Giuntini D, Picco P, Brandi ML, Falcini F.
    Arthritis Rheum; 2000 Sep 15; 43(9):1960-6. PubMed ID: 11014345
    [Abstract] [Full Text] [Related]

  • 16. Treatment with alendronate plus calcium, alendronate alone, or calcium alone for postmenopausal low bone mineral density.
    Bonnick S, Broy S, Kaiser F, Teutsch C, Rosenberg E, DeLucca P, Melton M.
    Curr Med Res Opin; 2007 Jun 15; 23(6):1341-9. PubMed ID: 17594775
    [Abstract] [Full Text] [Related]

  • 17. Effects of oral alendronate in elderly patients with osteoporosis and mild primary hyperparathyroidism.
    Rossini M, Gatti D, Isaia G, Sartori L, Braga V, Adami S.
    J Bone Miner Res; 2001 Jan 15; 16(1):113-9. PubMed ID: 11149474
    [Abstract] [Full Text] [Related]

  • 18. The upper GI safety and tolerability of oral alendronate at a dose of 70 milligrams once weekly: a placebo-controlled endoscopy study.
    Lanza F, Sahba B, Schwartz H, Winograd S, Torosis J, Quan H, Reyes R, Musliner T, Daifotis A, Leung A.
    Am J Gastroenterol; 2002 Jan 15; 97(1):58-64. PubMed ID: 11808969
    [Abstract] [Full Text] [Related]

  • 19. Randomized trial of effect of alendronate continuation versus discontinuation in women with low BMD: results from the Fracture Intervention Trial long-term extension.
    Ensrud KE, Barrett-Connor EL, Schwartz A, Santora AC, Bauer DC, Suryawanshi S, Feldstein A, Haskell WL, Hochberg MC, Torner JC, Lombardi A, Black DM, Fracture Intervention Trial Long-Term Extension Research Group.
    J Bone Miner Res; 2004 Aug 15; 19(8):1259-69. PubMed ID: 15231012
    [Abstract] [Full Text] [Related]

  • 20. Prevention of bone loss in paraplegics over 2 years with alendronate.
    Zehnder Y, Risi S, Michel D, Knecht H, Perrelet R, Kraenzlin M, Zäch GA, Lippuner K.
    J Bone Miner Res; 2004 Jul 15; 19(7):1067-74. PubMed ID: 15176988
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.